U.S. Tuberous Sclerosis Drugs Market – Industry Trends and Forecast to 2030

U.S. Tuberous Sclerosis Drugs Market Analysis and Size

The U.S. tuberous sclerosis drugs market is increasing significantly due to factors such as FDA approval of new drugs for the treatment of tuberous sclerosis. In 3 in every 4 cases, the genetic fault occurs in people no affected family members with this disease. Tuberous sclerosis causes mild disease in which individuals are left untreated in adulthood or it can cause major risks that can impact quality of life or the disorder small red spots appear between the ages of 3 and 5 years, mostly on the face and appear in a butterfly pattern.   

Data Bridge Market Research analyses a growth rate in the tuberous sclerosis drugs market in the forecast period 2023-2030. The expected CAGR of tuberous sclerosis drugs market is tend to be around 23.10% in the mentioned forecast period. The market value is USD 237.2 million in 2022, and it would grow upto USD 1250.7 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

U.S. Tuberous Sclerosis Drugs Market Scope and Segmentation

Market Definition

Tuberous sclerosis is a type sporadic genetic, chronic disorder. The disorder is related with the formation of benign (non-cancerous) tumors in numerous organ of the body. The tumors are termed hamartomas, which is tumor-like propagated growth that consist of cells usually found in the area where the hamartoma formation occurs. The signs and symptoms of this disorder can vary person to person, and also among members of the same family, which is hereditary.

U.S. Tuberous Sclerosis Drugs Market Dynamics

Drivers

• Increasing prevalence of tuberous sclerosis

Tuberous sclerosis is a type of rare genetic disorder that affects mostly around 1 in 6,000 newborns in the U.S. Around 40,000 to 80,000 people in the U.S. have tuberous sclerosis. The occurrence in Europe is expected to be around 1 in 25,000 to 1 in 11,300. Males and females are largely affected in equal numbers and the disorder occurs in all races and ethnic groups. Thus, this increasing inicidence demands a high amount of drugs which boost the market's growth.

• Growing demand of diagnostic options

There are varied diagnostic options for tuberous sclerosis that boost the demand of the market. Molecular genetic testing can help in confirming a diagnosis of tuberous sclerosis. A number of tests can be used to help obtain a diagnosis of tuberous sclerosis or to evaluate or establish the extent of the disorder in an individual. Such tests include scanning and magnetic resonance imaging (MRI), computerized tomography (CT) to assess the brain for the wide presence of tumors or other brain involvement. Furthermore, tests such as an echocardiogram and an electrocardiogram (EKG) can be widely used to assess the heart for the presence of a rhabdomyoma. Thus, this boost the market growth.

Opportunities

• Growing product launches by organizations

There has been an increasing number of product launches that are helpful in developing the market growth. Two drugs have been approved by the U.S. Food and Drug Administration for treating seizures associated with tuberous sclerosis. Also, in 2018, FDA approved Afinitor (everolimus) used for the treatment of seizures in pediatric and adult patients aged 2 years and above with tuberous sclerosis, and Epidiolex (cannabidiol) for patients one year and above in 2020. Thus, these product launches are boosting the growth of the market.

• Increasing demand of mTOR inhibitors

Individuals under mTOR inhibitors for internal tumors may witness improvement in skin lesions. Topical formulations of mTOR inhibitors have shown great improvement in treating facial angiofibromas. For instance, the FDA approved mTOR inhibitors' use to treat lung complications such as Lymphangioleiomyomatosis (LAM) in individuals with tuberous sclerosis in 2015. Lymphangioleiomyomatosis occurs frequently in young women of childbearing age, therefore scientists have expected that female hormones such as estrogen play a major role i​​​​​​​n the development of the disorder. Thus, this rising adoption of mTOR inhibitors help in market growth.

Restraints/Challenges

• High cost of drugs

Many drugs are associated with tuberous sclerosis such as conventional, anticonvulsants drugs, anti-seizure medication and numerous methods of rehabilitative and behavioral therapy. Majority of these treatment methods cost high. These drugs process causes the increased rate of cost. Thus, these factors restrict the market growth.

This tuberous sclerosis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tuberous sclerosis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

U.S. Tuberous Sclerosis Drugs Market Scope

The tuberous sclerosis drugs market is segmented on the basis of gene, site, drug class, drugs type, population type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Gene

• TSC2
• TSC1

Site

• Brain
• Kidney
• Skin
• Heart
• Lungs
• Others

Drug Class

• mTOR inhibitors
• Anti-Convulsants
• Cannabidiol or Epidiolex
• Others

Drug Type

• Branded
• Generics

Population Type

• Children
• Adults

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Specialty Clinics
• Academic & Research Institutes
• Others

Distribution Channel

• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy

Competitive Landscape and U.S. Tuberous Sclerosis Drugs Market Share Analysis

The tuberous sclerosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, U.S. presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tuberous sclerosis drugs market.

Key players operating in the tuberous sclerosis drugs market include:

• Sanofi (France)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Amgen inc. (U.S.)
• Lilly (U.S.)
• AstraZeneca (U.K.)
• AbbVie Inc (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• LEO Pharma A/S (Denmark)
• Merck & Co., Inc (U.S.)
• Bausch Health Companies Inc (Canada)
• Bristol-Myers Squibb Company (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Par Pharmaceutical (U.S.)
• Dr Reddy’s Laboratories Ltd (India)
• Jazz Pharmaceuticals, Inc (U.K.)
• Hikma Pharmaceuticals PLC (U.K.)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• VistaPharm, Inc. (U.S.)

SKU-61183